Hers BBB and Consumer-Complaint Trends: What the Data Actually Shows

What Is Hers and How Does Its Model Work?

Hers is the women-focused brand within Hims & Hers Health, a publicly traded direct-to-consumer telehealth company. Patients complete an online intake, consult asynchronously or via video with a licensed clinician, and receive prescriptions shipped directly to their door on a recurring subscription. Services span hormone replacement therapy (HRT), GLP-1-based weight management, mental health (including SSRI/SNRI prescriptions), hair regrowth, and skincare.

The subscription architecture and why it matters for complaints

The subscription model is the single largest source of friction documented in consumer complaints. Charges recur automatically. Patients report difficulty locating a clear cancellation path, receiving charges after they believed a subscription was cancelled, and being billed for shipments they did not receive. This pattern is not unique to Hers, it appears across D2C telehealth broadly, but the scale of the Hims & Hers platform amplifies it.

Who actually owns Hers?

Hims & Hers Health, Inc. Files with the SEC and reports earnings quarterly. Its annual report (10-K) discloses subscriber counts, revenue, and churn. In Q4 2024, Hims & Hers reported approximately 2.0 million subscribers across both brands. At that scale, even a low complaint-to-subscriber ratio produces a large absolute number of BBB filings.

BBB Rating and Complaint Volume: Reading the Data Correctly

The Better Business Bureau gives Hims & Hers an "F" rating. That letter grade reflects the volume of unresolved or late-resolved complaints relative to the company's size and time in business. The BBB does not assess clinical quality, prescribing accuracy, or patient outcomes.

What an "F" BBB rating does and does not mean

An "F" rating means the BBB believes the company has not addressed complaint patterns adequately or has a high volume of complaints relative to its size. It does not mean the company is fraudulent, unlicensed, or clinically dangerous. Several large legitimate companies carry poor BBB ratings because their complaint volume outpaces their resolution bandwidth.

For Hers specifically, the BBB profile lists over 1,500 complaints closed in the last three years. Billing and collection issues account for roughly 60% of those filings, based on category breakdowns visible on the BBB profile page. Problems with a product or service account for most of the remainder.

Complaint resolution rate

The BBB records whether a company responds to and resolves complaints. Hims & Hers does respond to the majority of filed complaints, which is why the profile shows "complaints closed" rather than "complaints ignored." The F rating reflects the pattern and frequency of complaints, not a refusal to engage. Patients who escalate through the BBB portal typically receive a customer-service response within 5 to 10 business days, based on the timestamps visible on closed complaint entries.

How to interpret complaint density for a 2-million-subscriber platform

At 2.0 million active subscribers and roughly 500 new BBB complaints per year, the complaint rate is approximately 0.025% of the subscriber base annually. That figure does not minimize individual patient harm, but it provides proportion. For comparison, major pharmacy chains and large insurance carriers with similar transaction volumes carry hundreds to thousands of BBB complaints per year without regulators classifying them as bad actors.

FDA Oversight and Regulatory Standing

GLP-1 compounded products and the 503B question

Hers expanded aggressively into GLP-1 weight-loss prescriptions in 2023 and 2024, offering compounded semaglutide and tirzepatide. The FDA placed semaglutide on its shortage list in 2022, which temporarily permitted 503A compounding pharmacies to produce it. The FDA removed semaglutide from the drug shortage list in February 2024 and issued guidance clarifying that 503A pharmacies could no longer compound copies of Ozempic or Wegovy [1]. Hims & Hers, including the Hers brand, continued offering compounded semaglutide after that deadline, prompting the FDA to send a warning letter to the company in March 2025 [2].

That warning letter is a material regulatory event. It does not constitute a criminal charge or a finding that patients were harmed, but it signals the FDA's view that the company was operating outside the permitted compounding window. The FDA's official drug shortage database is the authoritative source for current shortage status [3].

LegitScript certification

LegitScript, the internet pharmacy verification service that Google and major ad networks use to approve pharmaceutical advertising, lists Hers as a certified telehealth provider [4]. LegitScript certification requires verifiable state licensure, a licensed prescriber review process, and compliance with applicable pharmacy laws. The certification is renewed periodically and can be revoked. Its existence at the time of writing means Hers met LegitScript's standards as of its most recent audit cycle.

State medical board licensing

Hers employs or contracts with licensed prescribers in each state where it operates. Telehealth prescribing requires a valid prescriber-patient relationship under applicable state law. No state medical board had issued a public disciplinary action specifically against the Hers platform as of July 2025. Individual prescriber disciplinary records are publicly searchable through state medical board websites, and the Federation of State Medical Boards maintains a national directory [5].

HRT-Specific Complaints and Clinical Considerations

What patients report about Hers HRT

Hormone replacement therapy through Hers typically involves estradiol patches, pills, or vaginal rings, plus progesterone for patients with an intact uterus. Complaint patterns related to HRT cluster around three themes: prescriptions written without an in-person exam (which some patients wanted but the model does not include), delays in receiving medication after the prescription is approved, and difficulty adjusting doses through the asynchronous chat interface.

The Menopause Society (formerly NAMS) 2023 position statement on menopause hormone therapy states that hormone therapy "remains the most effective treatment for vasomotor symptoms and is approved for prevention of bone loss" in appropriate candidates [6]. The clinical indication is well-established. The question Hers patients raise is not whether HRT works, but whether a text-based intake and asynchronous prescriber is sufficient for individualized dosing.

Is asynchronous prescribing adequate for HRT?

Asynchronous telehealth (the model Hers uses) is legal in most states for HRT. The American College of Obstetricians and Gynecologists (ACOG) has noted that telehealth can expand access to menopause care, particularly in regions with limited specialist availability [7]. The tradeoff is that asynchronous models lack the back-and-forth needed to quickly resolve side effects or titrate doses. Patients who experience breakthrough bleeding, mood changes, or other HRT side effects report waiting days to weeks for a clinician response through the Hers messaging interface, based on complaint patterns in BBB filings.

Weight-Loss Service Complaints and GLP-1 Supply Problems

GLP-1 receptor agonists, particularly semaglutide and tirzepatide, drove Hers subscriber growth in 2023 and 2024. They also drove a spike in complaints.

Compounded semaglutide availability disputes

After the FDA removed semaglutide from the shortage list and Novo Nordisk (the maker of Ozempic and Wegovy) objected to compounded versions, many Hers patients received notices that their compounded semaglutide would be discontinued. Some received mid-cycle notifications after already paying for the next shipment. Complaint filings related to GLP-1 services rose sharply in late 2024 and early 2025, based on the date stamps on BBB complaint filings.

The FDA's position is clear: once a drug is removed from the shortage list, compounding that drug without a specific patient need documented by a licensed prescriber is not permitted under section 503A of the Federal Food, Drug, and Cosmetic Act [1].

Transition to branded GLP-1 medications

Hers responded to the shortage-list removal by attempting to transition patients to branded Wegovy or Ozempic via prior authorization. Prior authorization success rates depend on the patient's insurer, BMI, and comorbidities. The CDC defines obesity as BMI 30 or higher, and most commercial insurers require a BMI of 30 (or 27 with a qualifying comorbidity) for GLP-1 coverage [8]. Patients who did not meet criteria faced abrupt discontinuation of their weight-loss medication, a known clinical risk given the rebound weight gain documented in STEP-4 (N=803), where semaglutide discontinuation led to regain of approximately two-thirds of lost weight within 52 weeks [9].

Mental Health Services: Prescribing Pattern and Complaint Profile

What Hers offers for mental health

Hers prescribes SSRIs (primarily sertraline and escitalopram) and SNRIs for anxiety and depression through an asynchronous intake. Prescriptions are issued after a text-based questionnaire and a short video or messaging consultation. Refills are managed through the app.

PHQ-9 and GAD-7 in asynchronous models

Validated tools like the PHQ-9 (Patient Health Questionnaire-9) and GAD-7 (Generalized Anxiety Disorder 7-item scale) can be administered via text-based intake, which is a defensible clinical practice [10]. The concern raised in complaints is not the use of screening tools, but what happens after prescribing begins. Patients report difficulty reaching a clinician when they experience side effects, want to taper, or are concerned about interactions. The FDA's prescribing information for sertraline includes a boxed warning about increased suicidality in patients under 25, monitoring obligations that are harder to fulfill asynchronously [11].

State regulations and telehealth mental health prescribing

Several states have tightened telehealth prescribing rules for controlled substances and, separately, for initial SSRI prescriptions without an in-person visit. Ryan Haight Online Pharmacy Consumer Protection Act requirements and DEA telehealth prescribing rules apply to controlled substances; SSRIs are not controlled, so Hers faces fewer regulatory barriers there. But state medical board rules vary, and this area of telehealth law remains actively evolving.

Hair Loss Complaints: Lower Volume, Lower Stakes

Hair-loss products from Hers (topical minoxidil, oral minoxidil, and spironolactone for androgenetic alopecia) generate a smaller share of total complaints. The clinical evidence base for these treatments is established: a meta-analysis published in JAMA Dermatology found topical minoxidil significantly improved hair density vs. Placebo in women with androgenetic alopecia [12]. Complaints in this category center on product quality (inconsistent concentration in compounded formulations), shipment delays, and auto-refill charges.

Spironolactone 25 to 200 mg daily is commonly used off-label for female pattern hair loss and requires monitoring of serum potassium, particularly in patients on ACE inhibitors or with kidney disease. A recurring complaint: patients report not receiving guidance on monitoring labs after being prescribed spironolactone through Hers.

How to Evaluate Whether Hers Is Right for You: A Decision Framework

Choosing Hers (or any D2C telehealth platform) for ongoing hormone or medication management involves weighing access convenience against clinical oversight depth. The following criteria help structure that decision.

When Hers may be a reasonable fit

• You need a first prescription for a low-complexity condition (mild vasomotor symptoms, mild depression, early androgenetic alopecia) and lack convenient local access to a clinician.
• You understand that asynchronous care means follow-up response times measured in hours to days, not minutes.
• You are comfortable managing billing and subscription settings proactively, including screenshot documentation of cancellation confirmations.
• Your state's telehealth laws permit asynchronous prescribing for your intended treatment.

When you should seek a traditional or hybrid care model instead

• You have a complex HRT history, prior cardiovascular events, or are a BRCA carrier, where the 2022 USPSTF recommendation against routine HRT for chronic disease prevention applies and individualized risk assessment is essential [13].
• You are under 25 and seeking an SSRI, given the FDA's boxed warning about suicidality monitoring obligations.
• You want GLP-1 therapy and your BMI is <30 without a documented comorbidity, making branded-product insurance coverage unlikely.
• You have had a prior billing dispute with a subscription telehealth service.

Practical steps before subscribing

1. Screenshot the pricing page and subscription terms before entering payment information.
2. Verify your state's telehealth prescribing rules for your specific treatment at your state medical board's website.
3. Check the LegitScript directory to confirm Hers's current certification status.
4. Ask explicitly, in the intake messaging, which pharmacy will fill your prescription and whether it is a 503A or 503B facility.

What Regulators Have Said: A Factual Summary

The FDA's March 2025 warning letter to Hims & Hers (parent of Hers) addressed the continued distribution of compounded semaglutide after the drug shortage designation expired [2]. The letter requested specific corrective actions and a response timeline. Warning letters do not constitute criminal findings. The FDA posts all issued warning letters publicly, and the Hims & Hers letter is searchable on the FDA warning letters database [2].

No state attorney general had filed a consumer-protection action specifically against the Hers brand as of July 2025. The FTC has issued broader guidance on negative-option subscription practices (the automatic-renewal model Hers uses), and the FTC's 2023 "click-to-cancel" rulemaking would, if fully implemented, require companies using subscription models to make cancellation as easy as sign-up [14]. That rule's enforcement status was still being litigated as of mid-2025.

The American Association of Clinical Endocrinology (AACE) published 2023 guidelines on obesity pharmacotherapy noting that GLP-1 receptor agonists are first-line agents for weight management in patients with BMI 30 or above (or BMI 27 with at least one weight-related comorbidity), and that prescribing through telehealth platforms is clinically appropriate when proper screening is performed [15]. The guidelines do not endorse specific telehealth vendors.

As Dr. Rekha Kumar, endocrinologist and former chief medical officer at Found Health, stated in a 2024 interview with Medscape: "The clinical evidence for GLP-1s is not in question. What we need to scrutinize is whether the prescribing platform ensures appropriate patient selection, monitoring, and follow-up." That standard applies directly to Hers and every comparable platform.

Is Hers Legit? The Direct Answer

Yes, Hers is a licensed telehealth provider. It employs licensed clinicians, uses a certified pharmacy network, holds LegitScript certification, and is subject to FDA and state medical board oversight. "Legit" and "without complaints" are different things. The BBB record, the 2025 FDA warning letter, and the pattern of billing complaints are real. Patients who engage with Hers should do so with clear expectations about the model's limits, particularly around asynchronous follow-up and subscription management.

The clinical services Hers offers are grounded in evidence-based medicine for the conditions they treat. The execution of those services, specifically the billing architecture, the GLP-1 compounding timeline, and the depth of follow-up care, is where documented problems concentrate.

If you are pursuing GLP-1 therapy through any telehealth platform, confirm that the pharmacy filling your prescription is operating within current FDA compounding rules before your first payment clears.